View all news

Staten Island University Hospital in New York Adds New Noninvasive Patient Monitoring Capabilities With System-Wide Conversion to Masimo Oximetry Technology

05/12/2010
Hospital Adds 51 Noninvasive Hemoglobin Monitors to Advance Bloodless Medicine

IRVINE, Calif., May 12, 2010 /PRNewswire via COMTEX/ --Staten Island University Hospital and Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, today jointly announced the system-wide conversion of Staten Island University Hospital to Masimo's advanced noninvasive oximetry technology. The conversion ensures that all hospital patients will be noninvasively monitored using the most technologically and clinically-advanced oximetry technology available--providing immediate, real-time measurements that help clinicians more rapidly assess, diagnose, and treat patients.

As part of the conversion, 51 noninvasive hemoglobin monitors have been installed in key care areas throughout the hospital--allowing clinicians to noninvasively measure patient hemoglobin levels in seconds, without the pain and delay associated with traditionally invasive blood tests.

"We wanted access to the most advanced noninvasive oximetry technologies available throughout our entire hospital system and that's exactly what our conversion to Masimo enables," stated Charles T. Vonfrolio, M.D., Director of Anesthesia at Staten Island University Hospital. "Masimo Rainbow SET capabilities provide real-time measurements and new clinical detail that expand patient monitoring beyond the traditional standard of care. With continuous tracking and trending of hemoglobin, fluid status, oxygen, carbon monoxide, and methemoglobin blood levels, we're able to make better healthcare decisions, faster."

The system-wide conversion standardizes all Staten Island University Hospital's sites of care to Masimo technology, including two campuses and 714 hospital beds, which involved upgrading the hospital's multi-parameter patient monitors, pulse oximeters, and sensors. Masimo offers the only upgradable pulse oximetry technology platform--Masimo Rainbow SET Pulse CO-Oximetry--that allows hospitals to add breakthrough noninvasive blood constituent measurement capabilities that previously required invasive procedures. The ability to continuously and noninvasively measure total hemoglobin (SpHb(R)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), PVI(R), and acoustic respiration rate (RRa(TM)), in addition to Masimo SET 'gold standard' Measure-Through Motion and Low Perfusion oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR) simultaneously facilitates earlier detection of life-threatening conditions and helps to guide treatment options.

According to Masimo Executive Vice President of Medical Affairs, Michael O'Reilly, M.D., "Staten Island University Hospital's commitment to leverage state-of-the-art medical technology for the betterment of patient care was a driving force in their decision to upgrade their oximetry technology. Their system-wide conversion to Masimo provides an advanced technology platform offering state-of-the-art noninvasive measurement capabilities they can use today with the ability to easily add new measurements in the future."

About Staten Island University Hospital

Staten Island University Hospital, a member of the North Shore-LIJ Health System, is a 714-bed, specialized teaching hospital located in New York City's 5th and fastest-growing borough. Occupying two large campuses, plus a number of community-based health centers and labs, the hospital provides quality care to the people of Staten Island, the New York metropolitan region, and to patients from around the world. For more information visit www.siuh.edu.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(R), in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced Masimo Rainbow SET(R) Acoustic Monitoring(TM), the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo's Rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo SET and Masimo Rainbow SET oximetry technologies will provide sufficient sensitivity and specificity to accurately detect physiological abnormalities and potentially life-threatening conditions in real-time for all patients, risks related to our belief that Masimo SET and Rainbow SET measurements will help clinicians guide treatment options, risks related to our assumptions regarding the repeatability of clinical results, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

    Media Contacts:
    Dana Banks               Arleen Ryback
    Masimo Corporation       Staten Island University Hospital
    (949) 297-7348           (718) 226-2483
    dbanks@masimo.com        arleen_ryback@siuh.edu


Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo

Multimedia Files:

Categories: Press Releases
View all news